David Chung Lands Top Job at Heart Repair Technologies

There’s a new leader in charge at Heart Repair Technologies Inc.

The company recently named David H. Chung as CEO. “David’s considerable experience in the heart valve space will be an invaluable asset to HRT as we prioritize an aggressive transcatheter development program,” Heart Repair Technologies (HRT) Board Director Rich Ferrari said. “With a strong background in early device development, operations and commercial expertise, we believe that David is the right leader to capitalize on HRT’s current momentum and drive our next phase of growth.”

Chung has more than 30 years of experience in the healthcare industry, mostly within the medtech and cardiovascular sectors, where he has a proven track record of leading global commercial organizations and guiding transformational growth. Chung most recently served as president and CEO of NeoChord Inc., a transcatheter technology company specializing in mitral valve prolapse treatment. From 2011-2012 he was president and CEO of Mitralis, an early-stage mitral valve repair company.

“David is uniquely suited to lead the company as we reach our next stage of development. HRT is preparing for the first-in-human study for our transcatheter mitral and tricuspid bridge devices, leveraging the long-term clinical success of our predicate, surgical device, which received CE Mark approval in 2017,” Founder/Director/HRT Board Director Dr. V.A. (Mani) Subramanian stated. “It’s an exciting time in HRT’s story, and David is the obvious choice to lead the organization into our next stage.”

Chung began his career at Pfizer and later spent more than 15 years at Edwards Lifesciences, where he ultimately served as vice president of North American Sales and Marketing for the Heart Valve Therapy Franchise and global vice president of Commercial Operations.

Chung earned a bachelor of science degree in engineering from the United States Military Academy at West Point and served as a PATRIOT Missile Officer in the U.S. Army with multiple distinctions, including recognition as an Operation Desert Storm Veteran and as an Airborne Badge and Bronze Star Medal recipient.

“I am confident the company’s differentiated technology with a transcatheter delivery will broadly reach the large, unmet patient population suffering from heart failure,” Chung commented. “I look forward to delivering on our strategic objectives as we advance the development of this device to a regulatory approval.”

Heart Repair Technologies Inc. (HRT) is a privately-held medical device company that designs, develops, and commercializes transcatheter solutions for treating heart failure patients suffering from mitral and tricuspid regurgitation. The company’s Trans Annular Bridge (TAB) System is designed to correct the core clinical issue of a large central gap between the anterior and posterior annuli, while preserving native annular motion and subvalvular apparatus. The surgical version of the device received CE Mark approval for the mitral position, providing a strong clinical foundation for the transcatheter delivery system’s development. HRT is headquartered in San Jose, Calif.